Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 28 February 1997:
Vol. 275. no. 5304, pp. 1263 - 0
DOI: 10.1126/science.275.5304.1263
Prev | Table of Contents | Next

Research News

Eliot Marshall

Half a dozen groups are vying for priority on CCR5--the receptor HIV uses to enter cells early in an infection--and many are filing patents. But these competitors may themselves be surprised to learn that a company that was not directly involved in these HIV studies--Human Genome Sciences of Rockville, Maryland--appears to have beaten everyone to the patent office.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)